Made-for-Purpose Manufacturing Solutions – The Key to CommercializationPublished: February 11, 2019
With an ever increasing number of cell and gene therapies approaching commercialization, the key needs for the industry in terms of improved manufacturing equipment are threefold: GMP-ready equipment, process scalability and affordability.
Until now, the industry largely relied upon retrofitting existing equipment from the blood processing and biologics sectors to fit its needs. In order to truly see a step change in improved manufacturing it is crucial for tool providers to design equipment specifically for the GMP environment. Watch this On Demands webinar with Nina Bauer, Brian Dutra and Shirae Leslie of FloDesign Sonics as they reveal the latest data on the development of the most cutting edge of novel bioprocessing tools. During the webinar, they discuss:
- Manufacturing cost drivers and key risk factors to commercial success.
- Current State of Affairs in manufacturing technologies
- How can we achieve commercially viable routine in manufacturing?
- What is acoustophoresis and why is it important to cell processing?
Dr Nina Bauer
VP Business Development, FloDesign Sonics Inc
Nina Bauer, a key figure in the cell and gene therapy community joined FloDesign Sonics in September as VP of Business Development. She leads the commercial aspects of establishing, launching, and further adoption of this disruptive technology. Previously Nina led Lonza’s Autologous Cell Therapy business, with manufacturing sites in the US and Europe. As part of this role, she was also in charge of establishing novel manufacturing technologies, most notably the Octane Cocoon™ platform. Prior to joining Lonza, Nina held business development roles at the Cell Therapy Catapult (London), and the University of Edinburgh, and worked as Life Science Consultant for regenerative medicine businesses.